FindTrial
Sign In

Comparative efficacy and safety of lorlatinib and alectinib for ALK rearrangement positive advanced non-small cell lung cancer in Asian and non-Asian patients: systematic review and network meta-analysis.

Comparative efficacy and safety of lorlatinib and alectinib for ALK rearrangement positive advanced non-small cell lung cancer in Asian and non-Asian patients: systematic review and network meta-analysis. - lorlatinib versus alectinib

Status
Active, not recruiting
Phases
Unknown
Study type
Unknown
Source
JPRN
Registry ID
JPRN-UMIN000043994
Enrollment
1000
Registered
2021-04-22
Start date
2021-04-21
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

non-small cell lung cacner

Interventions

None listed

Sponsors

Showa University school of medicine
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Phase 3 randomized trials of patients with ALK positive ALK naive advanced non-small cell lung cancer with PS of 0-2

Exclusion criteria

Exclusion criteria: Studies for children Observational studies

Design outcomes

Primary

MeasureTime frame
Progression free survival(PFS) overall survival(OS) Grade 3 or higher of adverse events (G3-AEs) in overall participants and subgroup with Asian and non-Asian patients—

Secondary

MeasureTime frame
Progression free survival(PFS) overall survival(OS) Grade 3 or higher of adverse events (G3-AEs) in patients with or without central nervous system metastasis and in subgroup by PS Objective response rate (ObR) Incidence of Any grade of any adverse events Incidence of Any grade and grade 3 or higher of serious adverse events, nausea, diarrhea, increased AST levels, increased ALT levels, and pneumonitis.—

Countries

Japan

Contacts

Public ContactKoichi Ando

Showa University school of medicine Department of Medicine, Division of Respiratory Medicine and Allergology,

koichi-a@med.showa-u.ac.jp03-3784-8532

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026